--- title: "LB Pharmaceuticals Raises $100 Million in Private Placement with Shares and Pre-Funded Warrants Issued" description: "LB Pharmaceuticals Inc. has raised $100 million through a private placement, issuing pre-funded warrants for 1,417,107 shares and 3,306,571 shares of common stock to institutional investors. Each pre-" type: "news" locale: "en" url: "https://longbridge.com/en/news/274977918.md" published_at: "2026-02-05T13:04:06.000Z" --- # LB Pharmaceuticals Raises $100 Million in Private Placement with Shares and Pre-Funded Warrants Issued > LB Pharmaceuticals Inc. has raised $100 million through a private placement, issuing pre-funded warrants for 1,417,107 shares and 3,306,571 shares of common stock to institutional investors. Each pre-funded warrant is priced at $21.1699, which is the common stock price minus a nominal exercise fee. The funds will support a Phase 2 trial for LB-102, aimed at treating major depressive disorder, and for general corporate purposes. LB Pharmaceuticals Inc. has announced the issuance of pre-funded warrants to purchase up to 1,417,107 shares of its common stock as part of a private placement. The pre-funded warrants were offered alongside 3,306,571 shares of common stock to select institutional investors. The purchase price for each pre-funded warrant is $21.1699, reflecting the per share purchase price for common stock less the $0.0001 per share exercise price. This private placement is expected to raise approximately $100 million in gross proceeds, with the funds intended to support a Phase 2 trial for LB-102 as an adjunctive treatment for major depressive disorder and for general corporate purposes. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LB Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9649345) on February 05, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) ### Related Stocks - [LBRX.US - LB Pharmaceuticals](https://longbridge.com/en/quote/LBRX.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | LB Pharmaceuticals 启动 LB-102 用于治疗双相抑郁症的二期临床试验 | LB Pharmaceuticals Inc. 已启动一项第二阶段临床试验 ILLUMINATE-1，以评估 LB-102 对双相抑郁症的疗效和安全性。该试验将在美国的 30 个地点招募约 320 名患者，参与者将在六周内接受 25 毫克或 | [Link](https://longbridge.com/en/news/273704681.md) | | 礼来公司声明：Mirikizumab 在中国获批用于治疗中度至重度克罗恩病和溃疡性结肠炎 | 礼来：Mirikizumab 在中国获得批准用于治疗中重度克罗恩病和溃疡性结肠炎 - 公司声明 | [Link](https://longbridge.com/en/news/275551012.md) | | 08:00 ET 研究表明，GLP-1 受体激动剂与无糖尿病患者的哮喘加重减少有关 | 在 2026 年 AAAAI 年会上发布的研究表明，胰高血糖素样肽-1 受体激动剂（GLP-1）显著减少了超重、肥胖和重度肥胖且没有糖尿病的患者的哮喘加重情况。研究发现，超重患者的加重风险降低了 14.6%，肥胖患者降低了 12.2%，重度 | [Link](https://longbridge.com/en/news/276005992.md) | | Arteris Inc. 的首席执行官 Charles Janac 报告了普通股的出售 | 阿特里斯公司（Arteris Inc.）首席执行官查尔斯·K·贾纳克（Charles K. Janac）报告了作为受益所有者出售普通股的情况。完整的文件可通过提供的链接获取。此消息由公共技术公司生成，仅供参考，不应被视为财务或法律建议。原始 | [Link](https://longbridge.com/en/news/275675466.md) | | 董事 Jorge Titinger 报告出售 FormFactor Inc.普通股 | 乔治·蒂廷杰（Jorge Titinger），FormFactor Inc. 的董事，已报告出售该公司的普通股。完整的文件可通过提供的链接获取。此消息由公共技术公司生成，仅供参考，不应被视为财务或法律建议。FormFactor Inc. 于 | [Link](https://longbridge.com/en/news/275519004.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.